Minerva Neurosciences | NERV - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Adma Biologics USD 50.29M 12.46M 2026-03
ALKERMES USD -65.93M 17.65M 2026-06
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
AstraZeneca USD 3.16B 3.95B 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Cipla INR 8.88B 2.74B 2026-06
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD -9.02M 65.06M 2026-03
CSL USD 2.64B 1.97B 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 7.48B 860M 2026-06
Merck USD 840M 2.72B 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novartis USD 4.75B 515M 2026-06
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 667M 4.32B 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Takeda JPY 201.42B 215.04B 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12